atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. Proactive: Hello you're watching Proactive. Joining me is atai Life Sciences CEO and co-founder, Dr Srinivas Rao. Srinivas, very good to speak with you. There's lots of exciting updates announced ...